These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 25337673)

  • 1. AXL kinase as a novel target for cancer therapy.
    Wu X; Liu X; Koul S; Lee CY; Zhang Z; Halmos B
    Oncotarget; 2014 Oct; 5(20):9546-63. PubMed ID: 25337673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications.
    Zhu C; Wei Y; Wei X
    Mol Cancer; 2019 Nov; 18(1):153. PubMed ID: 31684958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research Progress of Axl Inhibitors.
    Sun ZG; Liu JH; Zhang JM; Qian Y
    Curr Top Med Chem; 2019; 19(15):1338-1349. PubMed ID: 31218961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer.
    Tanaka M; Siemann DW
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerating AXL targeting for TNBC therapy.
    Khera L; Lev S
    Int J Biochem Cell Biol; 2021 Oct; 139():106057. PubMed ID: 34403827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells.
    Corno C; Gatti L; Lanzi C; Zaffaroni N; Colombo D; Perego P
    Curr Med Chem; 2016; 23(15):1496-512. PubMed ID: 27048336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic aspects of the Axl/Gas6 molecular system.
    Di Stasi R; De Rosa L; D'Andrea LD
    Drug Discov Today; 2020 Dec; 25(12):2130-2148. PubMed ID: 33002607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells.
    Vouri M; An Q; Birt M; Pilkington GJ; Hafizi S
    Oncotarget; 2015 Jun; 6(18):16183-97. PubMed ID: 25980499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors.
    Linger RM; Keating AK; Earp HS; Graham DK
    Expert Opin Ther Targets; 2010 Oct; 14(10):1073-90. PubMed ID: 20809868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axl inhibitors as novel cancer therapeutic agents.
    Shen Y; Chen X; He J; Liao D; Zu X
    Life Sci; 2018 Apr; 198():99-111. PubMed ID: 29496493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AXL receptor as an emerging molecular target in colorectal cancer.
    De Rosa L; Di Stasi R; Fusco V; D'Andrea LD
    Drug Discov Today; 2024 Jun; 29(6):104005. PubMed ID: 38685399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor.
    Zhang H; Peng X; Dai Y; Shao J; Ji Y; Sun Y; Liu B; Cheng X; Ai J; Duan W
    J Med Chem; 2021 Apr; 64(7):3956-3975. PubMed ID: 33733758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent discovery and development of AXL inhibitors as antitumor agents.
    Liu Z; Chen L; Zhang J; Yang J; Xiao X; Shan L; Mao W
    Eur J Med Chem; 2024 Jun; 272():116475. PubMed ID: 38714043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity.
    Kimani SG; Kumar S; Bansal N; Singh K; Kholodovych V; Comollo T; Peng Y; Kotenko SV; Sarafianos SG; Bertino JR; Welsh WJ; Birge RB
    Sci Rep; 2017 Mar; 7():43908. PubMed ID: 28272423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective.
    Myers SH; Brunton VG; Unciti-Broceta A
    J Med Chem; 2016 Apr; 59(8):3593-608. PubMed ID: 26555154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Axl improves the targeted therapy against ALK-mutated neuroblastoma.
    Xu F; Li H; Sun Y
    Biochem Biophys Res Commun; 2014 Nov; 454(4):566-71. PubMed ID: 25450694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers.
    Balaji K; Vijayaraghavan S; Diao L; Tong P; Fan Y; Carey JP; Bui TN; Warner S; Heymach JV; Hunt KK; Wang J; Byers LA; Keyomarsi K
    Mol Cancer Res; 2017 Jan; 15(1):45-58. PubMed ID: 27671334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axl Receptor Axis: A New Therapeutic Target in Lung Cancer.
    Levin PA; Brekken RA; Byers LA; Heymach JV; Gerber DE
    J Thorac Oncol; 2016 Aug; 11(8):1357-1362. PubMed ID: 27130831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer.
    Lin JZ; Wang ZJ; De W; Zheng M; Xu WZ; Wu HF; Armstrong A; Zhu JG
    Oncotarget; 2017 Jun; 8(25):41064-41077. PubMed ID: 28455956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies.
    Kariolis MS; Miao YR; Diep A; Nash SE; Olcina MM; Jiang D; Jones DS; Kapur S; Mathews II; Koong AC; Rankin EB; Cochran JR; Giaccia AJ
    J Clin Invest; 2017 Jan; 127(1):183-198. PubMed ID: 27893463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.